March 8, 2018 / 10:04 PM / 2 months ago

BRIEF-Pfizer Announces Favorable Outcome Of FDA Advisory Committee Meeting

March 8 (Reuters) - Pfizer Inc:

* PFIZER ANNOUNCES FAVORABLE OUTCOME OF FDA ADVISORY COMMITTEE MEETING ON XELJANZ® (TOFACITINIB) FOR MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

* PFIZER INC - ‍FDA’S DECISION ON WHETHER OR NOT TO APPROVE TOFACITINIB FOR UC IS EXPECTED BY PRESCRIPTION DRUG USER FEE ACT (PDUFA) DATE IN JUNE 2018​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below